https://doi.org/10.1007/s11626-020-00517-7

Xuefei Cao¹, Jayme P. Coyle², Rui Xiong¹, Yiying Wang¹, Robert H. Heflich¹, Baiping Ren¹, William M. Gwinn³, Patrick Hayden⁴, Liying Rojanasakul²

¹ Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., AR Jefferson, USA
² Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers forDisease Control and Prevention,Morgantown,WV, USA
³ Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Durham, NC, USA
⁴ BioSurfaces Inc., Ashland, MA, USA

One important element for validating any new assay for making regulatory decisions is determining its performance relative to an accepted standard. Conducting in vivo inhalation toxicity studies using whole-body or nose-only exposure systems is expensive and time-consuming and typically requires a large number of animals. The goal of using alternative methods, like human in vitro ALI airway cultures, ultimately is to replace inhalation toxicity testing in animals with in vitro approaches. Transition from animal- to human-based models is ultimately expected to lead to faster and better predictive toxicity assessments and therapeutic development at lower cost.  This study shows the development and validation of alternative in vitro methods for acute toxicity testing, including acute inhalation toxicity testing.
 

Read more

S. Steiner¹, Sandra Ferreira¹, Moran Morelli¹, Audrey Baldi¹, Arkadiusz K. Kuczaj¹, Stefan Frentzel¹, Marco van der Toorn¹, Manuel Peitsch¹, Julia Hoeng^1
1 PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000 Neuchâtel, Switzerland

This poster shows the investigation how aerosols are delivered within the Cloud SEQ 24 and how cell cultures respond to exposures in the system. Ibuprofen and Bortezomib was exposed to three dimensional organotypic tissue cultures of the human bronchial epithelium and biological endpoints were measured: Cytotoxicity, Interleukin 8 and Proteasome activity.

Read more

Following the VITROCELL® User Group Meeting 2018 in San Antonio, Texas, USA, international scientists from Europe, Japan, Korea and USA reconvened in March 2019.

The informal event organized into short presentations and posters was followed by open discussions. It was an excellent opportunity to discuss the latest developments of VITROCELL®, to exchange your experience in working with the equipment and to meet other fellow researchers.
The meeting took place prior to the international Society of Toxicology 58th Annual Meeting and ToxExpo, March 10 – 14, 2018, in Baltimore, USA - one of the largest international conferences related to toxicology.

Focus of the event was to share VITROCELL® activities since the last meeting, to exchange latest research results, to give an update on VITROCELL’s participation in major research programs as well as the presentation of new products for 2019.

Read more

DOI: 10.1089/jamp.2017.1364

Ivana d’Angelo, PhD,¹ Gabriella Costabile, PhD,^2,3 Estelle Durantie, PhD,³ Paola Brocca, PhD,⁴ Valeria Rondelli, PhD,⁴ Annapina Russo, PhD,⁵ Giulia Russo, PhD,⁵ Agnese Miro, PharmD,² Fabiana Quaglia, PhD,² Alke Petri-Fink, PhD,³ Barbara Rothen-Rutishauser, PhD,³ and Francesca Ungaro, PhD^2
1 Di.S.T.A.Bi.F., University of Campania ‘‘Luigi Vanvitelli,’’ Caserta, Italy.
² Laboratory of Drug Delivery, Department of Pharmacy, University of Napoli Federico II, Napoli, Italy.
³ Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland.
⁴ Applied Physics, Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.
⁵ Laboratory of Biochemistry, Department of Pharmacy, University of Napoli Federico II, Napoli, Italy.

The Vitrocell Cloud was used for the exposure to aerosolized nanoparticles on a in vitro three-dimensional cell cluture, mimicking the human epithelial airway barrier comprising human bronchial epithelial cells,human blood monocyte-derived macrophages and dendritic cells to show the optimized siRNA transport and delivery at lung.

Read more

Johannes Sood

VITROCELL Systems GmbH, 79183 Waldkirch, Germany

Read more